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Abstract 
A 70-year-old female patient presented with an eruption consisting of symmetrically 
distributed erythematous papules around the umbilicus 1 month after the cessation of 
adalimumab for the treatment of rheumatoid arthritis. Biopsy of a papule showed an 
interstitial granulomatous infiltrate in the dermis, without deposition of mucin. The lesions 
cleared only after re-initiation of treatment 2 months later. Interstitial granulomatous 
dermatitis is thought to be a distinct histopathological pattern, either drug induced or 
associated with rheumatoid arthritis or autoimmune collagen diseases. In our case, there 
was a distinct clinical presentation of interstitial granulomatous dermatitis, composed of 
symmetrically distributed indurated papules around the umbilicus as well as a mild 
granulomatous reaction pattern. 
 
Introduction 
Interstitial granulomatous dermatitis (IGD) is thought to be a distinct 
histopathological pattern. It is characterized by the presence of histiocytes in the 
dermis between the collagen bundles arranged separately or in groups. This pattern 
may be either drug induced or associated with rheumatoid arthritis (RA) or 
autoimmune collagen diseases. Here, we present a case of IGD with distinct clinical 
features in a female patient with RA. Case Rep Dermatol 2011;3:195–200 
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Case Report 
A 70-year-old woman with a 10-year history of RA, who was under treatment with adalimumab at 
a dose of 40 mg subcutaneously every 2 weeks for the last 2 years, decided to stop her injections. One 
month later, she presented to our department with an eruption consisting of symmetrically 
distributed erythematous papules around the umbilicus (fig. 1). 
Biopsy of a papule showed a normal epidermis and a perivascular and diffuse infiltration of the 
dermis by lymphocytes, histiocytes and a few giant cells, without deposition of mucin (fig. 2, fig. 3, 
fig. 4). Chest X-ray examination, tuberculin skin (PPD) test as well as QuantiFERON-TB test were all 
negative. ACE levels were within normal limits. 
The lesions showed no improvement after application of topical steroids and cleared only after 
re-initiation of adalimumab treatment 2 months later, at the same dose of 40 mg subcutaneously 
every 2 weeks. This treatment decision was mainly made by the rheumatologists, as the patient had 
an exacerbation of RA. 
Discussion 
IGD most often presents either as an interstitial granulomatous drug reaction (IGDR) 
or as IGD with arthritis (IGDwA). 
IGDR clinically presents as asymptomatic, annular, erythematous to violaceous 
plaques with a predilection for the intertriginous areas, medial thighs and inner aspects 
of the arms [1]. Causative medications include calcium channel blockers, ACE 
inhibitors, lipid-lowering agents, antihistamines, diuretics, anticonvulsants, ganciclovir, 
antidepressants, interleukin-1 antagonists, trastuzumab, thalidomide and anti-TNF 
agents [2–4]. 
Anti-TNF agents have been implicated in the pathogenesis of IGDRs with histological 
variations. Apart from the interstitial lymphohistiocytic infiltrate, focal vacuolar 
degeneration of the basement membrane, necrotic keratinocytes, interstitial 
eosinophils and mucin may be present [4]. Adalimumab has been reported twice to 
cause IGDR [4, 5]. 
IGDwA is a rare disorder described mostly in female patients with RA in association 
with a relapse of the disease or as a drug-related reaction. It usually presents with 
linear, elongated, dermal bands without epidermal changes on the trunk and 
extremities (‘rope’ sign) [6]. 
It is likely that IGDwA represents a reactive phenomenon. The origin of this disorder 
is still unclear. It has been stated to be caused by an antigen-antibody reaction with the 
formation of auto-antibodies, which may affect several organs (especially the skin and 
joints) [2]. The mechanism of IGDwA may also be related to the immune-modulating 
effects of biologic agents, which may alter the antigenicity of dermal collagen, elicit an 
immune response, or disturb the normal production of collagen in response to damage 
[6]. Moreover, the close association between the development of skin lesions after the 
initiation of anti-TNF therapy and the clearance or improvement of the skin lesions 
after discontinuation of TNF inhibitors suggests a role of the medication on the 
development of cutaneous lesions [4]. It is possible that anti-TNF agents enhance the 
likelihood of developing IGDwA in RA patients who have granulomatous diathesis, 
although the true incidence of IGDwA in RA patients with or without anti-TNF therapy Case Rep Dermatol 2011;3:195–200 
DOI: 10.1159/000332349 
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is not known. On the other hand, TNF is involved in a number of processes which help 
maintain granuloma induction of adhesion molecules, including endothelial cell 
activation, as well as growth of new blood vessels and regulation of other inflammatory 
cytokines [7]. Anti-TNF antibodies reduce all the above-mentioned interrelated 
activities and thus may be efficacious in the treatment of IGD, while cessation of them 
may induce granuloma formation again. 
In a similar case to ours, IGDwA developed after sudden discontinuation of anti-TNF 
therapy, and the restart of this medication led to the resolution of the skin lesions [7]. 
The fact that this disorder responds to immunomodulatory treatment is consistent with 
the hypothesis of an altered immunologic reactivity. 
In our case, there was a distinct clinical presentation of IGD, composed of 
symmetrically distributed indurated papules around the umbilicus as well as a mild 
granulomatous reaction pattern. The whole reaction was probably induced by the 
cessation of adalimumab and the subsequent gradual exacerbation of RA, although 
traces of the medication might still have been in the patient’s blood when the initial 
rash presented. 
In conclusion, with the increasing use of biologics worldwide, awareness of the 
clinical spectrum of drug- or RA-associated granulomatous lesions is continuously 
enriched. 
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Fig. 1. Erythematous papules around the umbilicus. 
 
 
Fig. 2. Infiltration of the dermis by lymphocytes and histiocytes, without deposition of mucin 
(HE ×10). 
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Fig. 3. Interstitial granulomatous infiltrate in the dermis (HE ×20). 
 
 
 
Fig. 4. Giant cell in the dermal infiltrate (HE ×40). 
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